On November 9, Hims & Hers Health Inc. fell 5.65% in Regular Trading, trading at $24.51 per share, with turnover of $67.80 million.

The most recent market interpretation tied the weakness to continued digestion of the company’s upcoming quarterly results and weight-loss drug partnership progress, while sentiment remained pressured by the earlier FTC complaint and subscription billing controversy.

Earlier, Eli Lilly and Hims & Hers Health Inc. announced an agreement to expand access to Zepbound and Foundayo through the Hims platform, allowing eligible patients to complete consultations, receive prescriptions, and order medicines at the same self-pay prices offered elsewhere. That development had previously lifted the shares, but subsequent trading indicates the positive catalyst was not enough to fully offset persistent regulatory and compliance-related concerns ahead of earnings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)